LH Labcorp
NYSE · SEC CIK 920148 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $13.70M 20 sales by 10 insiders
- Filings on record
- 414 since 2021-08-03, latest 2026-09-03 08:21
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Schechter Adam H | Pres, CEO, Dir | — | $8.44M |
| Parham Richelle P | Dir | — | $1.78M |
| Wilkinson Peter J | SVP, CAO | — | $1.06M |
| ANDERSON KERRII B | Dir | — | $954.1K |
| Caveney Brian J | EVP, CMO, CSO, Pres of ED | — | $429.5K |
| Meltzer Jonathan C | EVP, Ops | — | $298.8K |
| Summy Amy B. | EVP, CMO | — | $283.4K |
| Kyle Kathryn W | EVP, CLO | — | $227.4K |
| van der Vaart Sandra D | EVP, Corp. Affairs | — | $156.0K |
| Vaughn Bryan T | EVP, Pres, Diagnostics | — | $67.0K |
Transactions 566
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-08 | 2024-02-07 | LH | Schroeder Mark S | EVP, COO, Pres Diagnostics | M - OptEx | — | +680 | 7,663 | +10% | — |
| DM | 2024-02-08 | 2024-02-07 | LH | Schroeder Mark S | EVP, COO, Pres Diagnostics | F - Tax | $223.71 | -182 | 7,500 | -2% | -$40.7K |
| DM | 2024-02-08 | 2024-02-07 | LH | DiVincenzo Jonathan P. | EVP, Pres, Central Labs, Intl | F - Tax | $223.71 | -119 | 3,759 | -3% | -$26.6K |
| DM | 2024-02-08 | 2024-02-07 | LH | DiVincenzo Jonathan P. | EVP, Pres, Central Labs, Intl | M - OptEx | — | +362 | 3,800 | +11% | — |
| D | 2024-02-08 | 2024-02-07 | LH | Summy Amy B. | EVP, CMO | F - Tax | $223.71 | -73 | 3,951 | -2% | -$16.3K |
| D | 2024-02-08 | 2024-02-07 | LH | Summy Amy B. | EVP, CMO | M - OptEx | — | +224 | 4,024 | +6% | — |
| D | 2024-02-08 | 2024-02-07 | LH | Williams R Sanders | Dir | M - OptEx | — | +947 | 8,120 | +13% | — |
| D | 2024-02-08 | 2024-02-07 | LH | BERBERIAN LANCE | EVP, CIO, CTO | F - Tax | $223.71 | -94 | 23.4K | -0.4% | -$21.0K |
| D | 2024-02-08 | 2024-02-07 | LH | BERBERIAN LANCE | EVP, CIO, CTO | M - OptEx | — | +353 | 23.5K | +2% | — |
| D | 2024-02-08 | 2024-02-07 | LH | GRAHAM ANITA Z | EVP, CHRO | F - Tax | $223.71 | -107 | 292 | -27% | -$23.9K |
| D | 2024-02-08 | 2024-02-07 | LH | GRAHAM ANITA Z | EVP, CHRO | M - OptEx | — | +369 | 399 | +1,230% | — |
| D | 2024-02-06 | 2024-02-02 | LH | EISENBERG GLENN A | CFO, EVP | M - OptEx | — | +856 | 43.0K | +2% | — |
| D | 2024-02-06 | 2024-02-02 | LH | EISENBERG GLENN A | CFO, EVP | F - Tax | $221.54 | -228 | 42.8K | -0.5% | -$50.5K |
| D | 2024-02-06 | 2024-02-02 | LH | Summy Amy B. | EVP, CMO | F - Tax | $221.54 | -80 | 3,800 | -2% | -$17.7K |
| D | 2024-02-06 | 2024-02-02 | LH | Summy Amy B. | EVP, CMO | M - OptEx | — | +246 | 3,880 | +7% | — |
| D | 2024-02-06 | 2024-02-02 | LH | Schechter Adam H | Pres, CEO, Dir | F - Tax | $221.54 | -822 | 49.2K | -2% | -$182.1K |
| D | 2024-02-06 | 2024-02-02 | LH | Schechter Adam H | Pres, CEO, Dir | M - OptEx | — | +3,094 | 50.0K | +7% | — |
| D | 2024-02-06 | 2024-02-02 | LH | Wilkinson Peter J | SVP, CAO | M - OptEx | — | +131 | 2,218 | +6% | — |
| D | 2024-02-06 | 2024-02-02 | LH | Wilkinson Peter J | SVP, CAO | F - Tax | $221.54 | -45 | 2,173 | -2% | -$9,969 |
| D | 2024-02-06 | 2024-02-02 | LH | BERBERIAN LANCE | EVP, CIO, CTO | M - OptEx | — | +331 | 23.2K | +1% | — |
| D | 2024-02-06 | 2024-02-02 | LH | BERBERIAN LANCE | EVP, CIO, CTO | F - Tax | $221.54 | -89 | 23.1K | -0.4% | -$19.7K |
| D | 2024-02-06 | 2024-02-02 | LH | Schroeder Mark S | EVP, COO, Pres Diagnostics | F - Tax | $221.54 | -132 | 7,121 | -2% | -$29.2K |
| D | 2024-02-06 | 2024-02-02 | LH | Schroeder Mark S | EVP, COO, Pres Diagnostics | M - OptEx | — | +495 | 7,253 | +7% | — |
| D | 2024-02-06 | 2024-02-02 | LH | DiVincenzo Jonathan P. | EVP, Pres, Central Labs, Intl | F - Tax | $221.54 | -85 | 3,516 | -2% | -$18.8K |
| D | 2024-02-06 | 2024-02-02 | LH | DiVincenzo Jonathan P. | EVP, Pres, Central Labs, Intl | M - OptEx | — | +246 | 3,601 | +7% | — |
| D | 2024-02-06 | 2024-02-02 | LH | Caveney Brian J | EVP, CMO, CSO, Pres of ED | F - Tax | $221.54 | -166 | 20.6K | -0.8% | -$36.8K |
| D | 2024-02-06 | 2024-02-02 | LH | Caveney Brian J | EVP, CMO, CSO, Pres of ED | M - OptEx | — | +495 | 20.8K | +2% | — |
| D | 2024-02-06 | 2024-02-02 | LH | van der Vaart Sandra D | EVP, CLO | M - OptEx | — | +264 | 7,901 | +3% | — |
| D | 2024-02-06 | 2024-02-02 | LH | van der Vaart Sandra D | EVP, CLO | F - Tax | $221.54 | -71 | 7,830 | -0.9% | -$15.7K |
| D | 2024-02-06 | 2024-02-05 | LH | van der Vaart Sandra D | EVP, CLO | S - Sale+OE | $220.57 | -193 | 7,637 | -2% | -$42.6K |
| D | 2023-12-19 | 2023-12-15 | LH | DiVincenzo Jonathan P. | EVP, Pres, Central Labs, Intl | M - OptEx | — | +64 | 3,374 | +2% | — |
| D | 2023-12-19 | 2023-12-15 | LH | DiVincenzo Jonathan P. | EVP, Pres, Central Labs, Intl | F - Tax | $219.50 | -19 | 3,355 | -0.6% | -$4,170 |
| 2023-11-20 | 2023-11-16 | LH | Wilkinson Peter J | SVP, CAO | S - Sale | $210.71 | -1,384 | 2,087 | -40% | -$291.6K | |
| D | 2023-10-16 | 2023-10-12 | LH | Kliphouse Kirsten Marie | Dir | M - OptEx | — | +372 | 372 | New | — |
| 2023-08-10 | 2023-08-08 | LH | ANDERSON KERRII B | Dir | S - Sale | $211.57 | -5,000 | 15.3K | -25% | -$1.06M | |
| D | 2023-08-03 | 2023-08-01 | LH | Wilkinson Peter J | SVP, CAO | M - OptEx | — | +56 | 3,488 | +2% | — |
| D | 2023-08-03 | 2023-08-01 | LH | Wilkinson Peter J | SVP, CAO | F - Tax | $213.61 | -17 | 3,471 | -0.5% | -$3,631 |
| 2023-07-03 | 2023-06-29 | LH | van der Vaart Sandra D | EVP, CLO | S - Sale | $240.00 | -212 | 7,605 | -3% | -$50.9K | |
| D | 2023-05-23 | 2023-05-19 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | $182.51 | +4,300 | 17.2K | +33% | +$784.8K |
| D | 2023-05-23 | 2023-05-19 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | S - Sale+OE | $216.91 | -4,300 | 12.9K | -25% | -$932.7K |
| D | 2023-05-22 | 2023-05-18 | LH | Schroeder Mark S | EVP, COO, Pres Diagnostics | S - Sale+OE | $216.77 | -1,500 | 6,687 | -18% | -$325.2K |
| D | 2023-05-22 | 2023-05-18 | LH | Schroeder Mark S | EVP, COO, Pres Diagnostics | M - OptEx | $130.60 | +1,500 | 8,187 | +22% | +$195.9K |
| 2023-04-03 | 2023-03-30 | LH | EISENBERG GLENN A | CFO, EVP | F - Tax | $224.70 | -5,179 | 42.2K | -11% | -$1.16M | |
| 2023-04-03 | 2023-03-30 | LH | EISENBERG GLENN A | CFO, EVP | A - Grant | $0.00 | +11.7K | 47.4K | +33% | $0 | |
| 2023-04-03 | 2023-03-30 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $224.70 | -2,886 | 12.9K | -18% | -$648.5K | |
| 2023-04-03 | 2023-03-30 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | A - Grant | $0.00 | +6,763 | 15.8K | +75% | $0 | |
| 2023-04-03 | 2023-03-30 | LH | BERBERIAN LANCE | EVP, CIO, CTO | F - Tax | $224.70 | -1,799 | 22.9K | -7% | -$404.2K | |
| 2023-04-03 | 2023-03-30 | LH | BERBERIAN LANCE | EVP, CIO, CTO | A - Grant | $0.00 | +4,509 | 24.7K | +22% | $0 | |
| 2023-04-03 | 2023-03-30 | LH | Wilkinson Peter J | SVP, CAO | A - Grant | $0.00 | +1,798 | 3,958 | +83% | $0 | |
| 2023-04-03 | 2023-03-30 | LH | Wilkinson Peter J | SVP, CAO | F - Tax | $224.70 | -526 | 3,432 | -13% | -$118.2K | |
| 2023-04-03 | 2023-03-31 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | S - Sale | $225.81 | -3,897 | 6,687 | -37% | -$880.0K | |
| 2023-04-03 | 2023-03-30 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | A - Grant | $0.00 | +6,763 | 13.5K | +101% | $0 | |
| 2023-04-03 | 2023-03-30 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | F - Tax | $224.70 | -2,866 | 10.6K | -21% | -$644.0K | |
| 2023-04-03 | 2023-03-30 | LH | Summy Amy B. | EVP, CMO | F - Tax | $224.70 | -1,269 | 3,634 | -26% | -$285.1K | |
| 2023-04-03 | 2023-03-30 | LH | Summy Amy B. | EVP, CMO | A - Grant | $0.00 | +3,234 | 4,903 | +194% | $0 | |
| 2023-04-03 | 2023-03-30 | LH | Schechter Adam H | Pres, CEO, Dir | A - Grant | $0.00 | +42.4K | 65.5K | +183% | $0 | |
| 2023-04-03 | 2023-03-30 | LH | Schechter Adam H | Pres, CEO, Dir | F - Tax | $224.70 | -18.6K | 46.9K | -28% | -$4.19M | |
| 2023-04-03 | 2023-03-30 | LH | Caveney Brian J | EVP, Pres of Diagnostics | F - Tax | $224.70 | -2,990 | 20.2K | -13% | -$671.9K | |
| 2023-04-03 | 2023-03-30 | LH | Caveney Brian J | EVP, Pres of Diagnostics | A - Grant | $0.00 | +6,763 | 23.2K | +41% | $0 | |
| 2023-04-03 | 2023-03-30 | LH | Seltz Judith C | EVP, CHRO | F - Tax | $224.70 | -1,164 | 4,182 | -22% | -$261.6K | |
| 2023-04-03 | 2023-03-30 | LH | Seltz Judith C | EVP, CHRO | A - Grant | $0.00 | +3,381 | 5,346 | +172% | $0 | |
| 2023-04-03 | 2023-03-30 | LH | van der Vaart Sandra D | EVP, CLO | A - Grant | $0.00 | +3,609 | 9,162 | +65% | $0 | |
| 2023-04-03 | 2023-03-30 | LH | van der Vaart Sandra D | EVP, CLO | F - Tax | $224.70 | -1,371 | 7,791 | -15% | -$308.1K | |
| D | 2023-03-06 | 2023-03-02 | LH | Summy Amy B. | EVP, CMO | F - Tax | $239.46 | -374 | 1,669 | -18% | -$89.6K |
| D | 2023-03-06 | 2023-03-02 | LH | Summy Amy B. | EVP, CMO | M - OptEx | — | +1,340 | 2,043 | +191% | — |
| D | 2023-02-23 | 2023-02-21 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | S - Sale+OE | $250.58 | -8,000 | 9,069 | -47% | -$2.00M |
| D | 2023-02-23 | 2023-02-21 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | $182.51 | +3,000 | 17.1K | +21% | +$547.5K |
| 2023-02-16 | 2023-02-14 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | S - Sale | $247.63 | -309 | 6,687 | -4% | -$76.5K | |
| D | 2023-02-14 | 2023-02-11 | LH | ANDERSON KERRII B | Dir | M - OptEx | — | +742 | 20.3K | +4% | — |
| D | 2023-02-14 | 2023-02-11 | LH | Williams R Sanders | Dir | M - OptEx | — | +742 | 7,173 | +12% | — |
| D | 2023-02-14 | 2023-02-11 | LH | BERBERIAN LANCE | EVP, CIO, CTO | M - OptEx | — | +290 | 20.3K | +1% | — |
| D | 2023-02-14 | 2023-02-13 | LH | BERBERIAN LANCE | EVP, CIO, CTO | F - Tax | $248.13 | -85 | 20.2K | -0.4% | -$21.1K |
| D | 2023-02-14 | 2023-02-11 | LH | Schechter Adam H | Pres, CEO, Dir | M - OptEx | — | +2,656 | 24.4K | +12% | — |
| D | 2023-02-14 | 2023-02-13 | LH | Schechter Adam H | Pres, CEO, Dir | F - Tax | $248.13 | -1,170 | 23.2K | -5% | -$290.3K |
| D | 2023-02-14 | 2023-02-13 | LH | Wilkinson Peter J | SVP, CAO | F - Tax | $248.13 | -38 | 2,160 | -2% | -$9,429 |
| D | 2023-02-14 | 2023-02-11 | LH | Wilkinson Peter J | SVP, CAO | M - OptEx | — | +110 | 2,198 | +5% | — |
| D | 2023-02-14 | 2023-02-11 | LH | NEUPERT PETER M | Dir | M - OptEx | — | +742 | 11.0K | +7% | — |
| D | 2023-02-14 | 2023-02-11 | LH | Seltz Judith C | EVP, CHRO | M - OptEx | — | +236 | 2,034 | +13% | — |
| D | 2023-02-14 | 2023-02-13 | LH | Seltz Judith C | EVP, CHRO | F - Tax | $248.13 | -69 | 1,965 | -3% | -$17.1K |
| D | 2023-02-14 | 2023-02-11 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | M - OptEx | — | +423 | 7,110 | +6% | — |
| D | 2023-02-14 | 2023-02-13 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | F - Tax | $248.13 | -114 | 6,996 | -2% | -$28.3K |
| D | 2023-02-14 | 2023-02-11 | LH | Kong Garheng | Dir | M - OptEx | — | +742 | 11.0K | +7% | — |
| D | 2023-02-14 | 2023-02-13 | LH | Caveney Brian J | EVP, Pres of Diagnostics | F - Tax | $248.13 | -124 | 16.4K | -0.7% | -$30.8K |
| D | 2023-02-14 | 2023-02-11 | LH | Caveney Brian J | EVP, Pres of Diagnostics | M - OptEx | — | +423 | 16.5K | +3% | — |
| D | 2023-02-14 | 2023-02-11 | LH | Parham Richelle P | Dir | M - OptEx | — | +742 | 7,587 | +11% | — |
| D | 2023-02-14 | 2023-02-11 | LH | BELINGARD JEAN-LUC | Dir | M - OptEx | — | +742 | 17.0K | +5% | — |
| D | 2023-02-14 | 2023-02-13 | LH | BELINGARD JEAN-LUC | Dir | F - Tax | $248.13 | -75 | 16.9K | -0.4% | -$18.6K |
| D | 2023-02-14 | 2023-02-11 | LH | Summy Amy B. | EVP, CMO | M - OptEx | — | +180 | 757 | +31% | — |
| D | 2023-02-14 | 2023-02-13 | LH | Summy Amy B. | EVP, CMO | F - Tax | $248.13 | -54 | 703 | -7% | -$13.4K |
| D | 2023-02-14 | 2023-02-11 | LH | Gilliland Dwight Gary | Dir | M - OptEx | — | +742 | 7,765 | +11% | — |
| D | 2023-02-14 | 2023-02-13 | LH | van der Vaart Sandra D | EVP, CLO | F - Tax | $248.13 | -78 | 5,553 | -1% | -$19.4K |
| D | 2023-02-14 | 2023-02-11 | LH | van der Vaart Sandra D | EVP, CLO | M - OptEx | — | +290 | 5,631 | +5% | — |
| D | 2023-02-14 | 2023-02-11 | LH | Davis Jeffrey A. | Dir | M - OptEx | — | +742 | 2,672 | +38% | — |
| D | 2023-02-14 | 2023-02-11 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | M - OptEx | — | +483 | 14.2K | +4% | — |
| D | 2023-02-14 | 2023-02-13 | LH | Kirchgraber Paul R | CEO, Covance Drug Development | F - Tax | $248.13 | -142 | 14.1K | -1.0% | -$35.2K |
| D | 2023-02-14 | 2023-02-11 | LH | Wengel Kathryn E | Dir | M - OptEx | — | +742 | 1,345 | +123% | — |
| D | 2023-02-14 | 2023-02-13 | LH | EISENBERG GLENN A | CFO, EVP | F - Tax | $248.13 | -195 | 35.6K | -0.5% | -$48.4K |
| D | 2023-02-14 | 2023-02-11 | LH | EISENBERG GLENN A | CFO, EVP | M - OptEx | — | +723 | 35.8K | +2% | — |
| D | 2023-02-09 | 2023-02-07 | LH | van der Vaart Sandra D | EVP, CLO | S - Sale | $243.01 | -219 | 5,341 | -4% | -$53.2K |
| D | 2023-02-09 | 2023-02-07 | LH | Schroeder Mark S | EVP, Pres-Diagnostics Lab | S - Sale | $243.01 | -409 | 6,687 | -6% | -$99.4K |
Purchase Sale Sale after option exercise All abbreviations